In a Phase 3 trial, the drug, which has the commercial name ELIQUIS, was compared with another drug, warfarin, in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.
Compared with warfarin, apixaban reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31% and mortality by 11%, the companies said.
The companies are developing the drug to prevent and treat blood clots."The risk for stroke in patients with atrial fibrillation is a major public health concern in an aging population," Dr. Christopher B. Granger, a professor of medicine at Duke University Medical Center and lead investigator of the study, was quoted saying in a news release from Bristol-Myers and Pfizer. > > Bull or Bear? Vote in Our Poll "We are therefore encouraged by the outcome of the ARISTOTLE trial, which showed that apixaban, as compared with warfarin, significantly reduced the risk of stroke or systemic embolism, major bleeding, and mortality," Granger said. The clinical trial results were presented at a medical conference in Paris and published in The New England Journal of Medicine. Shares of Bristol-Myers Squibb closed Friday up 24 cents at $28.72, while shares of Pfizer ended the session up 25 cents at $18.21.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV